Metabolism of melatonin by human cytochromes P450

Drug Metabolism and Disposition

Volumn 33, Issue 4, 2005, Pages 489-494

  Ma, Xiaochao ^a   Idle, Jeffrey R ^b   Krausz, Kristopher W ^a   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,3',5' TETRAMETHOXYSTILBENE; 6 HYDROXYMELATONIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 INHIBITOR; MELATONIN; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN HOMOGENATE; CONTROLLED STUDY; DEMETHYLATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME MECHANISM; HORMONAL REGULATION; HORMONE METABOLISM; HYDROXYLATION; IC 50; INTESTINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS; STRAIN DIFFERENCE; TISSUE DISTRIBUTION; WILD TYPE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; HYDROXYLATION; ISOENZYMES; MALE; MASS SPECTROMETRY; MELATONIN; MICE; MICE, KNOCKOUT;

EID: 15344344226     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002410     Document Type: Article

References (36)

1. Arendt J, Middleton B, Stone B, and Skene D (1999) Complex effects of melatonin: evidence for photoperiodic responses in humans? Sleep 22:625-635.
2. Barrenetxe J, Delagrange P, and Martinez JA (2004) Physiological and metabolic functions of melatonin. J Physiol Biochem 60:61-72.
3. Chen Z, Chua CC, Gao J, Hamdy RC, and Chua BH (2003) Protective effect of melatonin on myocardial infarction. Am J Physiol 284:H1618-H1624.
4. Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, and Stoilov I (2003) Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys 414:91-100.
5. Chun YJ, Kim S, Kim D, Lee SK, and Guengerich FP (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 61:8164-8170.
6. Delagrange P, Atkinson J, Boutin JA, Casteilla L, Lesieur D, Misslin R, Pellissier S, Penicaud L, and Renard P (2003) Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol 15:442-448.
7. Granberg L, Ostergren A, Brandt I, and Brittebo EB (2003) CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab Dispos 31:259-265.
8. Guengerich FP, Chun YJ, Kim D, Gillam EM, and Shimada T (2003) Cytcchrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524:173-182.
9. Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmark S, and Bertilsson L (2001a) Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 70:10-16.
10. Hartter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, and Hiemke C (2001b) Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 21:167-174.
11. Heiligenstein E and Guenther G (1998) Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian and kava-kava. J Am Coll Health 46:271-276.
12. Herxheimer A and Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev:CD001520.
13. Holliman BJ and Chyka PA (1997) Problems in assessment of acute melatonin overdose. South Med J 90:451-453.
14. Iba MM, Storch A, Ghosal A, Bennett S, Reuhl KR, and Lowndes HE (2003) Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch Toxicol 77:547-554.
15. Krusekopf S, Roots I, Hildebrandt AG, and Kleeberg U (2003) Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica 33:107-118.
16. Lahiri DK, Ge YW, Sharman EH, and Bondy SC (2004) Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res 36:217-223.
17. Lissoni P, Barni S, Crispino S, Tancini G, and Fraschini F (1989) Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 25:789-795.
18. Martin XD, Malina HZ, Brennan MC, Hendrickson PH, and Lichter PR (1992) The ciliary body-the third organ found to synthesize indoleamines in humans. Eur J Ophthalmol 2:67-72.
19. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, and Kadlubar FF (2001) In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 49:229-236.
20. Ng TB, Liu F, and Zhao L (2000) Antioxidative and free radical scavenging activities of pineal indoles. J Neural Transm 107:1243-1251.
21. Panzer A and Viljoen M (1997) The validity of melatonin as an oncostatic agent. J Pineal Res 22:184-202.
22. Reiter RJ and Tan DX (2003) What constitutes a physiological concentration of melatonin? J Pineal Res 34:79-80.
23. Reiter RJ, Tan DX, Osuna C, and Gitto E (2000) Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 7:444-458.
24. Reiter RJ, Tan DX, and Qi WB (1998) Suppression of oxygen toxicity by melatonin. Zhongguo Yaoli Xuebao 19:575-581.
25. Serie JB, Wang RF, Peterson WM, Plourde R, and Yerxa BR (2004) Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 13:385-388.
26. Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, and Yamazaki H (1997) Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 25:617-622.
27. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, and Thal LJ (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26:893-901.
28. Skene DJ, Papagiannidou E, Hashemi E, Snelling J, Lewis DF, Fernandez M, and Ioannides C (2001) Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res 31:333-342.
29. Skinner DC and Malpaux B (1999) High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 140:4399-4405.
30. Skwarlo-Sonta K (2002) Melatonin in immunity: comparative aspects. Neuroendocrinol Lett 23 (Suppl 1):61-66.
31. Thomas B and Mohanakumar KP (2004) Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36: 25-32.
32. Ursing C, Wikner J, Brismar K, and Rojdmark S (2003) Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J Endocrinol Investig 26:403-406.
33. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, and Rojdmark S (2000) Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 56:123-127.
34. Yeleswaram K, Vachharajani N, and Santone K (1999) Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications. J Pineal Res 26:190-191.
35. Young IM, Leone RM, Francis P, Stovell P, and Silman RE (1985) Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 60:114-119.
36. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, and Gonzalez FJ (2003) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173-181.